Home HLA and Immune Genetics HLA-B*58:01 Test: Allopurinol Severe Skin Reaction Risk and Results

HLA-B*58:01 Test: Allopurinol Severe Skin Reaction Risk and Results

By
Vita Library
-
3
Learn how HLA-B*58:01 testing estimates allopurinol severe skin-reaction risk, who may need testing, what results mean, safer dosing, alternatives, and urgent warning signs.

The HLA-B*58:01 test checks for an inherited immune-system allele strongly associated with allopurinol-induced severe cutaneous adverse reactions. These reactions include Stevens–Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms. They are rare but can cause extensive skin injury, liver or kidney damage, and death. Testing is most often considered before the first allopurinol dose in people with ancestry or clinical factors linked to higher risk, including many patients of Han Chinese, Korean, Thai, other Southeast Asian, or African American ancestry. A positive result generally leads to choosing a non-allopurinol urate-lowering strategy. A negative result lowers the genetic risk but does not eliminate severe reactions, especially when kidney disease, a high starting dose, or other risk factors are present. The genotype does not determine the correct allopurinol dose or whether uric acid will reach target. Any new rash, fever, facial swelling, mouth sores, skin pain, or systemic illness after starting allopurinol requires urgent medical assessment.

  • A positive HLA-B*58:01 result means allopurinol-associated SCAR risk is substantially increased, so another treatment is generally preferred.
  • A negative result reduces but does not remove SCAR risk; careful low-dose initiation and monitoring still matter.
  • Testing is most useful before the first allopurinol dose, because severe reactions usually begin during the first weeks to months.
  • No fasting is needed, and the test usually uses blood, saliva, or a cheek-swab DNA sample.
  • Kidney impairment, higher starting doses, and some ancestry backgrounds add risk independently of the allele.
  • Stop-and-seek-care symptoms include rash, blisters, skin pain, fever, facial swelling, mouth or eye sores, or signs of organ injury.

Table of Contents

What HLA-B*58:01 Testing Measures

HLA-B58:01 is a specific allele of the HLA-B gene. HLA-B proteins sit on the surface of most nucleated cells and present small peptide fragments to cytotoxic T cells. In people who carry HLA-B58:01, allopurinol or its active metabolite oxypurinol can contribute to an abnormal immune response that damages skin and internal organs.

The association is strongest with severe cutaneous adverse reactions, often shortened to SCAR. The major conditions are:

  • Stevens–Johnson syndrome and toxic epidermal necrolysis: painful skin and mucosal injury with blistering and detachment
  • DRESS: drug reaction with eosinophilia and systemic symptoms, often involving fever, facial swelling, rash, enlarged lymph nodes, abnormal blood counts, and liver, kidney, lung, or heart injury
  • Allopurinol hypersensitivity syndrome: a broad clinical term that may include DRESS, SJS/TEN, vasculitis, hepatitis, kidney injury, and systemic illness

The test is a preventive pharmacogenetic test. It does not measure serum urate, kidney function, gout severity, or allopurinol concentration. It does not predict whether allopurinol will lower uric acid enough or how many milligrams a patient will need.

People inherit one HLA-B allele from each biological parent. Detecting one copy of HLA-B58:01 is enough to classify the result as positive. The allele may appear as HLA-B58:01, HLA-B5801, or B58:01. A report that only says “HLA-B58” may lack the resolution needed for prescribing because the B58 family includes more than one allele.

The result remains the same throughout life. A validated previous result can usually be reused. However, a clinician should confirm that the earlier assay directly typed HLA-B*58:01 and that the sample was collected under circumstances that reflect the patient’s own DNA.

A positive result is a risk marker, not a diagnosis. Most carriers have never had a reaction because they have never taken allopurinol or because genetic susceptibility alone is not sufficient. A negative result is also not a guarantee: many SCAR cases occur in people without HLA-B*58:01, particularly across genetically diverse populations.

Who May Benefit From Testing

Testing is considered before allopurinol initiation when the expected allele frequency and the patient’s clinical risk make prevention especially valuable. The American College of Rheumatology conditionally recommends testing people of Southeast Asian descent—such as Han Chinese, Korean, or Thai ancestry—and African American patients before starting allopurinol. Other countries and health systems may use broader population strategies based on local allele frequencies and costs.

Ancestry is relevant because HLA-B*58:01 frequency varies. It is relatively common in several East and Southeast Asian populations and occurs at a higher frequency in many people of African ancestry than in most European populations. Country labels are imperfect. Frequency can differ within a nation, and mixed ancestry, migration, adoption, or unknown family history can obscure risk.

Testing may be especially reasonable when several factors combine:

  • ancestry linked to higher HLA-B*58:01 frequency
  • chronic kidney disease, particularly moderate to severe impairment
  • anticipated difficulty distinguishing a drug reaction from other illness
  • limited access to urgent specialist care
  • prior severe reaction in a close relative who may share the allele
  • use of other medicines or conditions that increase concern about a systemic reaction

Kidney impairment matters because oxypurinol is cleared mainly through the kidneys. Reduced clearance increases exposure, and chronic kidney disease is a well-established clinical risk factor for allopurinol hypersensitivity. Cardiovascular disease and use of thiazide diuretics have also appeared as risk markers in observational data, although their effects may overlap with kidney function and prescribing patterns.

Testing is usually not helpful after a patient has taken allopurinol continuously for months or years without hypersensitivity. Most cases occur within the first several weeks, and the vast majority develop within the first few months. A long-term tolerant patient should not stop effective therapy simply because testing was not done before initiation.

A patient with a previous allopurinol-associated SJS/TEN, DRESS, or convincing hypersensitivity syndrome should avoid allopurinol permanently, regardless of genotype. The clinical history already establishes a high-risk contraindication. Genetic testing cannot justify rechallenge.

Allopurinol should not be prescribed solely for asymptomatic hyperuricemia in most people. The decision to start urate-lowering treatment usually depends on gout attacks, tophi, uric acid kidney stones, very high serum urate, kidney disease, or other guideline-defined circumstances. HLA testing becomes relevant only after the clinician has determined that allopurinol is a reasonable treatment option.

How the Test Is Performed

The laboratory analyzes DNA from blood, saliva, or a buccal swab. No fasting is required, and gout flares, uric acid levels, diet, or current medicines do not alter the inherited genotype.

Testing methods include sequence-specific PCR, real-time PCR, probe-based assays, Sanger sequencing, and next-generation sequencing. A targeted assay reports whether HLA-B*58:01 is detected. Broader HLA-B testing can identify both HLA-B alleles and may provide higher resolution.

Turnaround time is often a few days but may extend to one or two weeks for send-out testing. If urate-lowering therapy is not urgent, clinicians can wait for the result. Gout flares can be treated with anti-inflammatory medicines while long-term therapy is planned.

A good report clearly states:

  • HLA-B*58:01 detected or not detected
  • the testing method or resolution
  • any assay limitations
  • whether the result is positive, negative, or indeterminate
  • a prescribing interpretation, when the laboratory provides one

An indeterminate result can occur because the sample contains too little DNA, the assay cannot distinguish a rare allele, or quality checks fail. It should not be treated as negative. Repeat collection or a different high-resolution method is appropriate before allopurinol exposure.

Testing after an allogeneic stem cell transplant needs special planning because blood cells may carry the donor’s HLA genotype. The laboratory may need a pre-transplant sample or a non-blood source. Routine red-cell transfusion usually has much less effect on genomic testing, but recent transfusion, transplant, or unusual sample circumstances should still be disclosed.

Consumer genetic data may impute HLA alleles from nearby markers instead of directly sequencing them. Imputation accuracy varies by ancestry and reference population. Because the result may determine whether a first-line medicine is used, clinical confirmation is necessary.

The genotype should be stored in a reusable medical-record field. A positive result can be linked to an allopurinol prescribing alert, while the exact report remains available for review. A negative result should be documented just as carefully so the patient does not undergo repeated testing.

Pre-test discussion should also address the tradeoff created by a positive result. Allopurinol is inexpensive, effective, and often the preferred first-line urate-lowering medicine, so avoiding it can affect cost, access, and long-term adherence. That does not weaken the safety recommendation; it means the clinician should identify a realistic alternative before ordering or acting on the test. Insurance coverage, kidney function, cardiovascular history, and local availability may determine which substitute is practical.

The test should be ordered by exact allele name. Requests written only as “HLA typing” may trigger a transplant-oriented panel that is broader, slower, or reported in a format not optimized for prescribing. Specifying HLA-B*58:01 for allopurinol sensitivity helps the laboratory select the correct assay and interpretation.

Interpreting Positive, Negative, and Unclear Results

Positive result

A positive result means at least one HLA-B*58:01 allele was detected. CPIC guidance recommends that allopurinol not be used and that an alternative be selected. The increased relative risk is large, although the absolute chance that any carrier will react remains much lower than 100%.

The result does not mean the person is allergic to all gout medicines. It is specific to the allopurinol risk association. Febuxostat, uricosuric medicines, anti-inflammatory drugs used for flares, and other treatments have separate safety profiles.

A positive result should be documented as “HLA-B*58:01 positive—avoid allopurinol due to SCAR risk.” A vague entry such as “sulfa allergy” or “gout medicine allergy” is inaccurate. Allopurinol is not a sulfonamide antibiotic, and grouping unrelated drugs can create unnecessary restrictions.

Negative result

A negative result means the allele was not detected. Allopurinol may be used when clinically indicated, but the clinician should still start at an appropriate low dose and titrate according to serum urate, kidney function, and tolerance.

Negative patients can still develop SCAR. Recent U.S. data found that a substantial fraction of allopurinol-SCAR cases did not carry HLA-B*58:01, confirming that the allele is an incomplete predictor. Other HLA alleles, non-HLA genes, kidney impairment, drug exposure, infections, and immune factors may contribute.

A negative test does not predict common side effects such as mild gastrointestinal symptoms. It also does not prevent rare liver injury, cytopenias, or other adverse events. Patients need symptom counseling and routine clinical monitoring.

Indeterminate or ambiguous result

An indeterminate result means the laboratory could not confidently establish HLA-B*58:01 status. The next step is usually repeat testing with a new sample or a method that provides higher resolution. Allopurinol initiation should generally wait when the patient belongs to a group for whom testing was considered important.

Some reports list HLA-B58 without the two-field allele. HLA-B58:02, for example, is not treated as equivalent to HLA-B*58:01. The exact allele is necessary. Laboratories familiar with pharmacogenetics can resolve uncommon ambiguities and explain whether a targeted assay could have cross-reactivity.

Treatment Choices After the Result

The test changes whether allopurinol is a preferred option; it does not establish the full gout treatment plan. Clinicians first confirm the indication for long-term urate lowering and set a serum urate target, commonly below 6 mg/dL for gout and sometimes lower in severe tophaceous disease.

For an HLA-B*58:01-negative patient, allopurinol is usually started low. Common starting approaches include no more than 100 mg daily in many adults and lower doses, such as 50 mg daily, in advanced chronic kidney disease. The dose is then increased gradually until the urate target is reached or intolerance limits treatment. Kidney disease does not prevent careful dose escalation; it mainly affects the starting dose, pace, and monitoring.

Starting low serves two purposes. It reduces early flare risk when paired with prophylaxis and may lower hypersensitivity risk associated with excessive initial exposure. The maintenance dose needed to reach target may eventually exceed traditional creatinine-clearance-based limits under specialist supervision.

When the result is positive, alternatives may include febuxostat or a uricosuric drug such as probenecid, depending on kidney function, cardiovascular history, stone risk, medication interactions, and local availability. Febuxostat also inhibits xanthine oxidase and can be effective in chronic kidney disease, but cardiovascular safety considerations and regulatory warnings must be reviewed for the individual patient. Probenecid is less effective with reduced kidney function and can increase uric acid stone risk.

Pegloticase is an intravenous uricase reserved for severe, refractory gout rather than routine first-line use. Specialist strategies may combine urate-lowering mechanisms in difficult cases. None of these decisions are made by HLA genotype alone.

Allopurinol desensitization has been used in selected patients with previous mild reactions when no suitable alternative exists. It is not appropriate after SJS/TEN, DRESS, or severe systemic hypersensitivity, and it is not a routine workaround for an HLA-B*58:01-positive patient. Any desensitization decision belongs with allergy, rheumatology, and other relevant specialists.

When urate-lowering therapy begins, gout flares may temporarily increase because urate deposits are mobilized. Colchicine, a nonsteroidal anti-inflammatory drug, or low-dose corticosteroid may be used as prophylaxis. A flare does not mean the urate-lowering drug has failed, and patients generally continue it unless a serious adverse reaction is suspected.

Recognizing Allopurinol Hypersensitivity

Severe reactions often begin within two to eight weeks, although onset can be earlier or occur during the first several months. Early symptoms may look like a viral illness or uncomplicated rash before organ injury becomes obvious.

Urgent warning signs include:

  • a spreading red, purple, target-like, blistering, or painful rash
  • skin peeling or tenderness
  • sores of the mouth, lips, eyes, or genitals
  • fever, marked fatigue, or flu-like illness
  • facial swelling or enlarged lymph nodes
  • shortness of breath, cough, or chest symptoms
  • dark urine, jaundice, severe nausea, or right-upper abdominal pain
  • reduced urine output, swelling, or sudden kidney-function decline
  • unusual bruising, bleeding, or signs of low blood counts

A person who develops these symptoms after starting allopurinol needs immediate clinical assessment. Severe reactions require prompt discontinuation and often hospital care. Allopurinol should never be restarted after suspected SJS/TEN, DRESS, or allopurinol hypersensitivity syndrome.

A simple, localized, itchy rash may be less severe, but it still warrants same-day prescriber contact because early SCAR can progress. Patients should not take another dose merely to see whether the rash worsens. Photographs and an accurate medication start date can help clinicians evaluate the reaction.

DRESS can continue or worsen after the drug is stopped because immune activation and organ inflammation may persist. Follow-up blood counts, liver tests, kidney tests, and sometimes cardiac or thyroid monitoring may be needed. SJS/TEN can cause long-term eye, skin, lung, or genital complications and requires multidisciplinary care.

Allopurinol hypersensitivity is distinct from an ordinary gout flare. A flare causes intense joint pain, swelling, warmth, and redness, often in one or a few joints, without the widespread rash and systemic features of SCAR. Confusing the two can lead either to unnecessary discontinuation or dangerous continued exposure.

Limitations and Safer Use

HLA-B*58:01 has one of the strongest known drug–HLA associations, but its predictive performance differs by population. The positive predictive value is low because SCAR is rare, even among carriers. The negative predictive value is high in many Asian populations but lower in settings where a larger share of cases occurs without the allele.

Testing does not replace these safer-use measures:

  • confirm that allopurinol is indicated
  • review kidney and liver function before treatment
  • start with a low dose and titrate rather than beginning high
  • consider flare prophylaxis
  • educate the patient about rash and systemic warning signs
  • review interacting medicines and comorbidities
  • monitor serum urate and adjust toward target
  • document any reaction precisely and avoid rechallenge after SCAR

The test also does not determine a “normal” or “abnormal” uric acid result. Serum urate is a separate biochemical measurement. A person can be HLA-B*58:01 positive with normal urate, or negative with severe gout. The HLA result only modifies medication safety.

Genetic associations continue to evolve. A 2025 study identified HLA-A34:02 as another independent risk factor in a U.S. cohort, while also confirming that HLA-B58:01 does not capture every case. That finding is not yet a universal replacement for established testing recommendations. Laboratories and guidelines need replication across populations before expanding routine panels.

Family members may share HLA-B*58:01, but routine cascade testing is not required because the allele does not cause illness without a relevant exposure. A relative can be tested when allopurinol is being considered. The result should not be interpreted as a general autoimmune-disease marker or used to predict gout inheritance.

When the clinical history is unclear, allergy specialists can help distinguish benign rash, DRESS, SJS/TEN, and unrelated illness. Skin testing and drug challenge are not routine ways to clear a patient after severe allopurinol reactions. The safest long-term record combines the exact phenotype, timing, genotype, and avoidance recommendation.

A negative HLA-B*58:01 result lowers the specific genetic risk but does not eliminate severe cutaneous adverse reactions. Kidney impairment, higher starting dose, older age, diuretic use, and clinical illness can add risk. Starting allopurinol at an appropriate low dose and titrating to the urate target remains important regardless of genotype.

A positive result usually leads clinicians to choose another urate-lowering strategy when possible. Febuxostat may be considered after review of cardiovascular history and local guidance. Uricosuric therapy depends on kidney function, stone history, drug interactions, and access. In rare cases where allopurinol is essential and alternatives are unsuitable, a specialist may consider desensitization, but this is not appropriate after severe cutaneous adverse reaction.

Patients should seek urgent care for rash with fever, facial swelling, mouth sores, eye pain, blisters, skin peeling, swollen lymph nodes, or signs of liver or kidney injury. Stopping the drug early is critical; waiting for the genotype or routine appointment can allow a severe reaction to progress.

References

Disclaimer

This article is educational and does not replace individualized gout treatment, pharmacogenetic interpretation, or emergency care. Do not start, stop, or restart allopurinol without the prescribing clinician’s guidance. Rash, blistering, skin pain, fever, facial swelling, mouth or eye sores, or signs of organ injury after allopurinol require urgent medical assessment.

RELATED ARTICLESMORE FROM AUTHOR